Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology • Stereotactic Radiosurgery • Medical Oncology • Breast Cancer, Metastatic
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
Answer from: Radiation Oncologist at Academic Institution
In a recently published study from Italy, Ippolito et al., PMID 35053467 a total of 10 patients with 32 HER2+ breast cancer brain metastases were treated with concurrent fSRT (27 Gy in 3 fractions) and Pertuzumab. Necrosis was reported in only 1 of the 32 treated lesions. The study is small but the ...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
We don’t hold for herceptin and pertuzumab for SRS but do hold for T-DM1 as it has increased risk of radionecrosis. Salvestrini et al., PMID 37437610
Answer from: Medical Oncologist at Academic Institution
Several retrospective studies have shown the good tolerance of concomitant radiotherapy with trastuzumab and pertuzumab either in loco-regional or distant metastatic disease. However, given the underlying mechanism of action, the use of antibody-drug conjugates of trastuzumab (trastuzumab emtan...